Pharmaceuticals Spain

Spain Lung Cancer Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Spain Lung Cancer Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Spain · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $655.9 Mn Placeholder estimate
Estimate 2025 $716.2 Mn 1.8% of the global market
Projected 2034 $1.58 Bn 120.8% Adds $865.2 Mn over 9 forecast years
CAGR 2025–2034 9.2% Faster than 63% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Spain is 1.79% of the global market.
  • In Europe, the largest is Germany at $1.60 Bn.
  • Fastest growing: Russia at 10.2% a year.
  • Spain ranks 5th of 6 by size in Europe.

Market size projection

Spain

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$865.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Lung Cancer Therapeutics Market market size by year, Spain
YearMarket sizeChange that yearSince 2025
2024 (estimate) $655.9 Mn — —
2025 (base) $716.2 Mn +$60.3 Mn —
2026 (forecast) $782.1 Mn +$65.9 Mn +9.2%
2027 (forecast) $854.0 Mn +$72.0 Mn +19.2%
2028 (forecast) $932.6 Mn +$78.6 Mn +30.2%
2029 (forecast) $1.02 Bn +$85.8 Mn +42.2%
2030 (forecast) $1.11 Bn +$93.7 Mn +55.3%
2031 (forecast) $1.21 Bn +$102.3 Mn +69.6%
2032 (forecast) $1.33 Bn +$111.7 Mn +85.2%
2033 (forecast) $1.45 Bn +$122.0 Mn +102.2%
2034 (forecast) $1.58 Bn +$133.2 Mn +120.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Spain Lung Cancer Therapeutics Market Analysis at a glance
Market size, 2025$716.2 Mn placeholder estimate
Forecast, 2034$1.58 Bn placeholder estimate
Growth (CAGR), 2025–20349.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, type and end user (see all)
Key playersMerck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and 1 more (see all)
Regulator in SpainAEMPSSource: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
Active clinical trials445 in SpainSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Spain Lung Cancer Therapeutics Market Analysis Executive Summary

Lung cancer therapeutics include targeted drugs, immunotherapy, chemotherapy and antibody-drug conjugates for small-cell and non-small cell lung cancer.

Key segments of the lung Cancer Therapeutics market include drug class (Targeted Therapy, Immunotherapy and Chemotherapy) and type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer).

Bar chart: Spain Lung Cancer Therapeutics market size, 2024–2034, placeholder estimates. $655.9 Mn in 2024, $716.2 Mn in 2025 and $1.58 Bn in 2034, 9.2% CAGR.
Spain Lung Cancer Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Spain Lung Cancer Therapeutics Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the lung Cancer Therapeutics market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the lung Cancer Therapeutics market, especially in low- and middle-income countries.

Competitive Landscape for Lung Cancer Therapeutics Market in Spain

The lung Cancer Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Lung Cancer Therapeutics Market in Spain

Lung Cancer Therapeutics in Spain: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices.⁠[1] The National Health System (SNS), run by the regions, gives universal public care.⁠[2] ClinicalTrials.gov lists 445 studies on Lung Cancer Therapeutics that are recruiting, active or about to start in Spain.⁠[3]

[1] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[2] Spanish Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lung Cancer Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Lung Cancer Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Lung Cancer Therapeutics in context

Spain compared

  • Health spending per person: 3,107 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.29 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 21.6% of people (2025). World: 10.4% of people (2025). 4th highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Lung Cancer Therapeutics market in Spain?
Placeholder estimate: about $716.2 Mn in 2025, rising to about $1.58 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lung Cancer Therapeutics market in Spain growing?
Placeholder estimate: about 9.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lung Cancer Therapeutics market report cover?
The report splits the market by drug class (Targeted Therapy, Immunotherapy, Chemotherapy, Antibody-Drug Conjugates), type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lung Cancer Therapeutics market?
Key players include Merck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and Johnson & Johnson.
What is driving the Lung Cancer Therapeutics market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
Who regulates Lung Cancer Therapeutics in Spain?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices. Source: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
How is healthcare paid for in Spain?
The National Health System (SNS), run by the regions, gives universal public care. Source: Spanish Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on Lung Cancer Therapeutics are running in Spain?
445 studies are recruiting, active or about to start in Spain, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
How much research is published on Lung Cancer Therapeutics?
PubMed lists 50 papers on Lung Cancer Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Spain

See all

Related on oncology and respiratory

See the topic